Infrastructure tools to support an effective radiation oncology learning health system

PF-3845
Clinical data
ATC code	None;
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name N-3-pyridinyl-4-([3-([5-(trifluoromethyl)-2-pyridinyl]oxy)phenyl]methyl)-1-piperidinecarboxamide;
CAS Number	1196109-52-0;
PubChem CID	25154867;
ChemSpider	26232165;
UNII	Q3PW846TYN;
CompTox Dashboard (EPA)	DTXSID40648905 ;
Chemical and physical data
Formula	C24H23F3N4O2
Molar mass	456.469 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(NC1=CN=CC=C1)N(CC2)CCC2CC3=CC=CC(OC4=NC=C(C(F)(F)F)C=C4)=C3;
	InChI InChI=1S/C24H23F3N4O2/c25-24(26,27)19-6-7-22(29-15-19)33-21-5-1-3-18(14-21)13-17-8-11-31(12-9-17)23(32)30-20-4-2-10-28-16-20/h1-7,10,14-17H,8-9,11-13H2,(H,30,32); Key:NBOJHRYUGLRASX-UHFFFAOYSA-N;

PF-3845 is a selective inhibitor of fatty acid amide hydrolase.^[1] It results in increased levels of anandamide and results in cannabinoid receptor-based effects. It has anti-inflammatory action in mice colitis models. Antidiarrheal and antinociceptive effects were also seen in mouse models of pain.^[2]

A 2017 study published in the Journal of Psychiatry and Neuroscience found that PF-3845 exerts rapid and long-lasting anti-anxiety effects in mice exposed acutely to stress or chronically to the stress hormone corticosterone.^[3]

References

^ Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, et al. (April 2009). "Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain". Chemistry & Biology. 16 (4): 411–20. doi:10.1016/j.chembiol.2009.02.013. PMC 2692831. PMID 19389627.
^ Fichna J, Sałaga M, Stuart J, Saur D, Sobczak M, Zatorski H, et al. (April 2014). "Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides". Neurogastroenterology and Motility. 26 (4): 470–81. doi:10.1111/nmo.12272. PMID 24460851. S2CID 2473356.
^ Duan T, Gu N, Wang Y, Wang F, Zhu J, Fang Y, et al. (June 2017). "Fatty acid amide hydrolase inhibitors produce rapid anti-anxiety responses through amygdala long-term depression in male rodents". Journal of Psychiatry & Neuroscience. 42 (4): 230–241. doi:10.1503/jpn.160116. PMC 5487270. PMID 28234213.

[1] Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, et al. (April 2009). "Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain". Chemistry & Biology. 16 (4): 411–20. doi:10.1016/j.chembiol.2009.02.013. PMC 2692831. PMID 19389627.

[2] Fichna J, Sałaga M, Stuart J, Saur D, Sobczak M, Zatorski H, et al. (April 2014). "Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides". Neurogastroenterology and Motility. 26 (4): 470–81. doi:10.1111/nmo.12272. PMID 24460851. S2CID 2473356.

[pmid28234213-3] Duan T, Gu N, Wang Y, Wang F, Zhu J, Fang Y, et al. (June 2017). "Fatty acid amide hydrolase inhibitors produce rapid anti-anxiety responses through amygdala long-term depression in male rodents". Journal of Psychiatry & Neuroscience. 42 (4): 230–241. doi:10.1503/jpn.160116. PMC 5487270. PMID 28234213.

[1]

[2]

[3]

Clinical data

ATC code	None
Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name N-3-pyridinyl-4-([3-([5-(trifluoromethyl)-2-pyridinyl]oxy)phenyl]methyl)-1-piperidinecarboxamide
CAS Number	1196109-52-0
PubChem CID	25154867
ChemSpider	26232165
UNII	Q3PW846TYN
CompTox Dashboard (EPA)	DTXSID40648905
Chemical and physical data
Formula	C₂₄H₂₃F₃N₄O₂
Molar mass	456.469 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=C(NC1=CN=CC=C1)N(CC2)CCC2CC3=CC=CC(OC4=NC=C(C(F)(F)F)C=C4)=C3
InChI InChI=1S/C24H23F3N4O2/c25-24(26,27)19-6-7-22(29-15-19)33-21-5-1-3-18(14-21)13-17-8-11-31(12-9-17)23(32)30-20-4-2-10-28-16-20/h1-7,10,14-17H,8-9,11-13H2,(H,30,32) Key:NBOJHRYUGLRASX-UHFFFAOYSA-N